Image

Health Ahead Comparative Effectiveness Study

Health Ahead Comparative Effectiveness Study

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.

The first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.

Description

Access to comprehensive preventive health screening is profoundly unequal. Geographic, economic, and systemic barriers leave medically underserved populations - including rural, frontier, and isolated communities - with little or no access to the depth of preventive screening that identifies disease before symptoms occur. The long-term aim of this work is a fully automated preventive screening system that can be deployed anywhere people live. Reaching that aim safely and credibly requires testing each change to the screening model one variable at a time, against current practice.

The Health Ahead Comparative Effectiveness Study is therefore designed as a standing sequential comparative-effectiveness platform. Each phase is a parallel two-arm comparison that isolates a single change while holding all other elements of the screening experience constant, and each is evaluated with the same core outcome set. As one comparison concludes, the next is opened by protocol amendment. Throughout, all participants are concurrently enrolled in the 100-Year Human Aging Study and the Human Observatory Study, so that short-horizon comparative findings are linked to lifelong individual and population-level outcomes.

Two design principles govern every comparison. First, allocation is randomized wherever randomization is feasible and non-randomized only where participant-level random assignment is not possible (for example, comparisons of screening location such as mobile versus fixed laboratory). Second, every comparison is registered with non-inferiority as the primary hypothesis: each evolutionary change toward a more automated and more broadly deployable model must demonstrate that it does not degrade outcomes relative to current practice, by more than a pre-specified margin. The unifying thesis is that quality is preserved as the platform evolves. Superiority is assessed as a pre-specified secondary in a hierarchical (gatekeeping) test and reported whenever non-inferiority is established and the data support a superiority claim. The same core outcome set is applied to every comparison to the greatest extent each comparison allows.

The planned comparison sequence is:

  • Comparison 1: Static versus interactive personalized health report delivery. Both arms complete identical comprehensive multi-system screening and differ only in the report they receive. The interactive report allows participants to adjust their own behaviors and diagnostic inputs in real time and visualize the projected effect on their composite scores, estimated biological age, and aging trajectory. Assignment is randomized. The primary hypothesis is that the interactive report is non-inferior to the standard static report on health activation and behavior change.
  • Comparison 2: Mobile community screening versus fixed laboratory screening in medically underserved populations. The question is whether mobile delivery achieves engagement and outcomes equivalent or superior to a fixed laboratory setting (an equivalence/non-inferiority question).
  • Comparison 3: A hybrid delivery model combining medical droids, one registered nurse, and remote physician oversight, versus human-only screening.
  • Future: Fully automated screening performed by medical droids with remote physician review versus hybrid model.

The platform launches in Colorado, chosen as the founding geography for its exceptional diversity of medically underserved communities - high-altitude frontier towns, rural agricultural communities, mining corridors, and isolated mountain communities - within a well-characterized geography with established academic research infrastructure. Findings are designed to generalize to medically underserved populations nationally, internationally, and to inform federal health policy on mobile and automated preventive health delivery.

Eligibility

Inclusion Criteria:

  • Age 18 years or older
  • Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
  • Willing to participate in longitudinal follow-up.

Exclusion Criteria:

\- Age under 18 years.

Study details
    Health Services Accessibility
    Rural Health
    Medically Underserved Area
    Preventive Health Services
    Patient Participation
    Health Behavior
    Aging
    Cardiovascular Diseases
    Metabolic Syndrome
    Cognitive Dysfunction
    Frailty
    Activities of Daily Living
    Health Related Quality of Life
    Health Equity
    Telemedecine

NCT07669168

William Brandenburg, MD

27 June 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.